🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,522 results for “solution” Clear

  1. Zimberelimab, CARBOPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOMVANALIMAB, CISPLATIN , PACLITAXEL , Abraxane 5 mg/ml powder for dispersion for infusion., ALIMTA 500 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Metastatic Non–Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  2. Zipalertinib Placebo Tablets is a film-coated tablet that does not contain the active ingredient, zipalertinib., Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Taiho Pharma Netherlands B.V.

    Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations

    phase 3 small molecule active

    1 trial

  3. Zolgensma 2 × 10^13 vector genomes/mL solution for infusion

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  4. Zometa 4 mg/100 ml solution for infusion

    Ningbo Cancer Hospital

    High grade osteosarcoma

    phase 3 small molecule active

    1 trial

  5. Zometa 4 mg/100 ml solution for infusion, XGEVA 120 mg solution for injection in pre-filled syringe

    CERO THERAPEUTICS HOLDINGS, INC.

    Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy

    phase 3 small molecule active

    1 trial

  6. Zydelig 100 mg film-coated tablets, Zydelig 150 mg film-coated tablets, Zydelig 150 mg film-coated tablets, Zydelig 150 mg film-coated tablets, Truxima 500 mg concentrate for solution for infusion, Truxima 500 mg concentrate for solution for infusion, Truxima 500 mg concentrate for solution for infusion, Zydelig 100 mg film-coated tablets, Bendamustin Hikma 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Bendamustin Hikma 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer I

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  7. bimatoprost ophthalmic solution formulation A

    Allergan Pharmaceuticals International Limited

    Glaucoma

    phase 3 small molecule terminated

    1 trial

  8. bimekizumab, Skyrizi 150 mg solution for injection in pre-filled syringe, Placebo matching test and comparator. 0.9% sodium chloride solution for injection (unauthorized).

    Lacuna Pharma Pty Ltd

    Psoriatic arthritis

    phase 3 small molecule active

    1 trial

  9. brivaracetam, -, -, brivaracetam, -, brivaracetam, Placebo matching < brivaracetam oral solution> and without active substance

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy Juvenile Absence Epilepsy

    phase 3 small molecule active

    1 trial

  10. commercially available saline solution for infusion, Amlenetug 53 mg/ml solution for infusion

    H. Lundbeck A/S

    Multiple System Atrophy

    phase 3 small molecule active

    1 trial

  11. elritercept, Placebo to match ker-050 solution for injection

    Takeda

    myelodysplastic neoplasms/syndromes (MDS)

    phase 3 small molecule active

    1 trial

  12. evorpacept, Herceptin 150 mg powder for concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/mL concentrate for solution for infusion, Normal Saline (Sodium Chloride)

    Wuhan Createrna Science and Technology Co., Ltd

    Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)

    phase 3 small molecule active

    1 trial

  13. mRNA-1647, Sodium Chloride 0.9%, Solution for Injection

    Moderna Biotech Spain

    Cytomegalovirus Infection (CMV)

    phase 3 small molecule active

    1 trial

  14. mRNA-4157, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    The participants must have a histologically confirmed diagnosis of resectable cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted).

    phase 3 small molecule active

    1 trial

  15. mRNA-4157, Saline solution for Placebo to v940 (mrna-4157), KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  16. normal saline solution for infusion, Ociperlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tislelizumab, Ociperlimab

    BeiGene

    Locally advanced, unresectable, or metastatic non small cell lung cancer

    phase 3 small molecule active

    1 trial

  17. placebo ketamine inj prep, KETAMINE RENAUDIN 10 mg/ml, solution injectable

    ISTA Pharma Limited

    Traumatism

    phase 3 small molecule active

    1 trial

  18. riliprubart placebo, solution for injection in prefilled pen (PFP), riliprubart placebo, solution for injection in vial, riliprubart, riliprubart

    Sanofi-aventis Healthcare Pty Ltd

    Polyneuropathy, Inflammatory Demyelinating, Chronic

    phase 3 small molecule active

    1 trial

  19. riliprubart, -, riliprubart placebo solution for injection in prefilled pen, placebo matching IVIg, riliprubart, riliprubart placebo solution for injection in vial, -

    Sanofi-aventis Healthcare Pty Ltd

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 3 small molecule active

    1 trial

  20. volrustomig, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Mycofit, 250 mg, kapsułki twarde, Remsima 100 mg powder for concentrate for solution for infusion

    AstraZeneca AB

    Metastatic Non-Small Cell Lung Cancer (mNSCLC)

    phase 3 small molecule active

    1 trial

  21. -, CYCLOPHOSPHAMIDE, Cesnicabtagene autoleucel, PARACETAMOL, FLUDARABINE, LENALIDOMIDE, RoActemra 20 mg/mL concentrate for solution for infusion

    The George Institute

    Plasma cell leukaemia

    phase 2 small molecule active

    1 trial

  22. -, Raludotatug Deruxtecan, MK-4830, MK-1308A, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, Lenvatinib, MK-4280A, DEXAMETHASONE , APREPITANT

    Merck Sharp and Dohme

    Participants with extensive-stage small cell lung cancer

    phase 2 small molecule active

    1 trial

  23. 0.9% Sodium chloride - inhalation solution

    Arrowhead Pharmaceuticals Ireland Limited

    Inflammatory Lung Disease

    phase 2 small molecule active

    1 trial

  24. 0.9% sodium chloride - inhalation solution, ARO-MUC5AC Inhalation Solution

    Arrowhead Pharmaceuticals Ireland Limited

    Asthma and Chronic obstructive pulmonary disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources